TNF and COVID-19: Among the IBD treatment modalities, corticosteroids could affect COVID-19 severity (P = .21, OR = 2.51, 95% CI [0.276–10.9]), whereas anti-TNFα antibodies (P < .001, OR = 0) and thiopurines (P = .038, OR = 0.16) were associated with a reduced risk of severe COVID-19.